

# Reprogramming Therapeutics: Synthetic Biological Constructs at the Frontier of Precision Medicine

Amol D. Gholap<sup>1</sup>, Navnath Hatvate<sup>2</sup>, Abdelwahab Omri<sup>3,\*</sup>

<sup>1</sup>Department of Pharmaceutics, St. John Institute of Pharmacy and Research, 401404 Palghar, India

<sup>2</sup>Institute of Chemical Technology, Marathwada Campus, 431213 Jalna, India

<sup>3</sup>The Novel Drug & Vaccine Delivery Systems Facility, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, ON P3E2C6, Canada

\*Correspondence: [aomri@laurentian.ca](mailto:aomri@laurentian.ca) (Abdelwahab Omri)

Published: 20 August 2025

## A Revolution Within Reach

Imagine a world where a single shot rewrites genetic destiny, engineered immune cells patrol the body like microscopic guardians, and chronic diseases vanish into medical history. This is not science fiction, but it is the near future promised by synthetic biology, advancing faster than even optimistic timelines predicted. The mRNA vaccines that halted the Coronavirus Disease 2019 (COVID-19) pandemic were just a preview [1]. Today, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) cures genetic disorders, Chimeric Antigen Receptor T (CAR-T) cells eradicate once-incurable cancers, and synthetic gene circuits detect diseases before symptoms appear [2]. Yet, we stand at a crossroads: These tools could democratize healthcare or deepen inequities. The choices we make now will determine whether synthetic biology becomes humanity's greatest medical triumph or a catalyst for division [3]. Synthetic biology merges engineering, biology, and computation to redesign living systems. Its core lies in programmability in designing cells to sense, compute, and respond to disease with precision. Unlike traditional therapies that manage symptoms, synthetic constructs target root causes, offering cures, not Band-Aids. But their success hinges on more than science; it requires ethical foresight and global collaboration [2].

## The Synthetic Biology Revolution: Beyond Treatment to Cure

The true power of synthetic biology lies in its capacity to redefine disease itself as presented in Fig. 1. Consider recent breakthroughs, including CRISPR-associated protein 9 (CRISPR-Cas9) has cured sickle cell anemia in clinical trials, offering lifelong relief with a single treatment. CAR-T cell therapies reprogram immune cells to obliterate cancers once deemed death sentences [4]. The mRNA platforms, proven during the pandemic, now target diseases from human immunodeficiency virus (HIV) to malaria. But the next wave is even more transformative. Epigenetic reprogramming could reverse aging, 3D-bioprinted organs might


eliminate transplant waitlists, and synthetic gene circuits could detect tumors years before they form. These innovations shift medicine from reactive to proactive, from generic to personalized, and from treatment to eradication [5,6].

## Engineering Life: The Science Behind the Promise

Synthetic biology's "BioBricks" with standardized genetic parts (promoters, enzymes, regulatory elements), which enable plug-and-play therapeutics. This modularity accelerates innovation: A gene circuit designed to combat diabetes could be repurposed to treat autoimmune disorders with minor tweaks. Open-source platforms like the BioBrick Registry democratize access, but outdated patent laws and proprietary silos threaten progress [7]. Engineered genetic circuits act as biological "software", directing cells to perform tasks with precision. For example, SynNotch CAR-T cells are programmed to recognize multiple cancer biomarkers, reducing off-target effects. Orthogonal systems containing genetic tools that operate independently of host biology to minimize unintended interactions, enhancing safety [8]. Lipid nanoparticles (LNPs) and engineered exosomes ferry synthetic constructs to target tissues. Advances in AI-driven design are optimizing these carriers for specificity, ensuring therapies reach the right cells at the right time [9].

## Breaking Down Barriers: Three Pillars for Responsible Innovation

The inequitable distribution of mRNA vaccines during the pandemic must never repeat. A Global SynBio Equity Fund, funded by tiered pricing in wealthy nations, could subsidize therapies for low-income countries. Open-source platforms and patent waivers for neglected diseases (e.g., sickle cell anemia) would prioritize health over profit. The power to edit life demands unprecedented responsibility. An International Bioethics Rapid Response Team should preempt crises, from designer babies to unintended ecosystem impacts. A global moratorium on heritable genome



**Fig. 1. Design principles and technological synergy in synthetic biology therapeutics.** (A) Programmable & Adaptive Constructs: Engineered biological systems with self-regulating feedback loops maintain physiological balance, minimize resistance, and ensure sustained therapeutic efficacy. Their adaptive design reduces side effects, enhancing long-term safety and precision. (B) Modular & Scalable Architecture: Interchangeable biological modules (e.g., promoters, enzymes) enable scalable assembly of gene circuits and metabolic pathways. This plug-and-play framework ensures predictable, customizable control over cellular processes. (C) Orthogonal Genetic Circuits: Synthetic circuits operate independently of host biology, minimizing unintended interactions. These systems enable precise dosage control and reliable regulation of cellular behavior, reducing off-target effects. (D) Convergence with Advanced Technologies: Integration with AI, nanotechnology, and precision engineering drives innovation in personalized medicine. Applications include AI-designed therapeutics, targeted gene-editing platforms, and smart delivery systems for oncology and regenerative medicine (Created with <https://www.biorender.com/>).

editing, paired with public dialogues on “acceptable” uses, would build trust [10]. Synthetic biology must intersect with AI, nanotechnology, and robotics. National Bio-Foundries, which are hubs integrating these fields, could slash development timelines. For example, AI-designed proteins could enable CAR-T therapies tailored to a patient’s unique cancer profile in weeks, not years. Regulatory sandboxes would allow rapid testing of high-impact

therapies, while interdisciplinary training programs cultivate a workforce fluent in biology, ethics, and engineering [11].

## Conclusion

The synthetic biology revolution is here. Scientists must share data openly, governments must invest in bio-infrastructure as a strategic priority, and industry leaders

must balance profit with planetary health. Citizens, too, have a role: Advocate for equitable access and engage with these technologies. This is not just about curing diseases, but it's about reimagining what it means to be human. Engineered probiotics could prevent diabetes before birth; synthetic organs could grant longevity without frailty. But technology alone is insufficient. We need systems that ensure these breakthroughs serve all humanity, not just the privileged few. The future of medicine is programmable, precise, and alive.

### Availability of Data and Materials

All data generated or analyzed during this study are included in this published article.

### Author Contributions

AO: Conceptualization, Data Curation, Formal Analysis. AG: Investigation, Visualization. NH: Data Curation. All authors were involved in the drafting and critical revision of the manuscript. All authors have read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

### Ethics Approval and Consent to Participate

Not applicable.

### Acknowledgment

Not applicable.

### Funding

This research received no external funding.

### Conflict of Interest

The authors declare no conflict of interest. Abdelwahab Omri is serving as one of the Editorial Board members of this journal. We declare that Abdelwahab Omri had no involvement in the review of this article and has no access to information regarding its review. Fig. 1 was created us-

ing Biorender. The authors have no financial or personal relationship with Biorender, and the use of this tool does not imply any endorsement.

### References

- [1] Leong KY, Tham SK, Poh CL. Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications. *Virology Journal*. 2025; 22: 71. <https://doi.org/10.1186/s12985-025-02645-6>.
- [2] Zhu B, Yin H, Zhang D, Zhang M, Chao X, Scimeca L, *et al*. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy. *Cellular & Molecular Immunology*. 2024; 21: 436–447. <https://doi.org/10.1038/s41423-024-01153-x>.
- [3] Feng Y, Su C, Mao G, Sun B, Cai Y, Dai J, *et al*. When synthetic biology meets medicine. *Life Medicine*. 2024; 3: Inae010. <https://doi.org/10.1093/lifemedi/lnae010>.
- [4] Tariq H, Khurshid F, Khan MH, Dilshad A, Zain A, Rasool W, *et al*. CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review. *Annals of Medicine and Surgery* (2012). 2024; 86: 5938–5946. <https://doi.org/10.1097/MS9.0000000000002478>.
- [5] Palacios S, Collins JJ, Del Vecchio D. Machine learning for synthetic gene circuit engineering. *Current Opinion in Biotechnology*. 2025; 92: 103263. <https://doi.org/10.1016/j.copbio.2025.103263>.
- [6] Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: The evolution of CAR-T cell therapy. *Molecular Therapy: the Journal of the American Society of Gene Therapy*. 2025; 33: 2123–2140. <https://doi.org/10.1016/j.ymthe.2025.03.005>.
- [7] Betz UAK, Arora L, Assal RA, Azevedo H, Baldwin J, Becker MS, *et al*. Game changers in science and technology-now and beyond. *Technological Forecasting and Social Change*. 2023; 193: 122588. <https://doi.org/10.1016/j.techfore.2023.122588>.
- [8] Müller MM, Arndt KM, Hoffmann SA. Genetic circuits in synthetic biology: broadening the toolbox of regulatory devices. *Frontiers in Synthetic Biology*. 2025; 3: 1548572. <https://doi.org/10.3389/fsybi.2025.1548572>.
- [9] Zhang T, Yin H, Li Y, Yang H, Ge K, Zhang J, *et al*. Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery *in vivo*. *iScience*. 2024; 27: 109804. <https://doi.org/10.1016/j.isci.2024.109804>.
- [10] Karataş P, Ayaz F. Synthetic biology and application areas. *Discover Biotechnology*. 2025; 2: 3. <https://doi.org/10.1007/s44340-025-00010-5>.
- [11] Lu L, Xie M, Yang B, Zhao WB, Cao J. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control. *Science Advances*. 2024; 10: eadj6251. <https://doi.org/10.1126/sciadv.adj6251>.